Celcuity Q2 FY26 net loss widens to $78.9 million; operating expenses climb to $66.1 million

Reuters2026/08/13 20:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Celcuity posted a GAAP net loss of $78.9 million, or $1.44 a share, widening from $45.3 million a year earlier.
Total operating expenses climbed to $66.1 million from $44 million, as SG&A jumped to $35 million from $7.6 million.
R&D slipped to $31.1 million from $36.4 million, on lower VIKTORIA-1 trial costs and reduced license milestone expenses.
Cash, cash equivalents and short-term investments rose to $754 million at quarter-end; net cash used in operations increased to $55.4 million.
Gedatolisib branded REVTORPYK won FDA clearance on July 14; Celcuity targets a late third-quarter 2026 US launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131606PRIMZONEFULLFEED9809923) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celcuity Q2 FY26 net loss widens to $78.9 million; operating expenses climb to $66.1 million

You may also like

Crypto prices